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ABSTRACT 
 
Effects of α-melanocyte stimulating hormone and 11β-hydroxysteroid 
dehydrogenase type 1 on sebogenesis in SZ95 sebocytes 
 
Ji Min Kim 
 
Department of Medical Science 
The Graduate School, Yonsei University  
 
(Directed by Professor Seung Hun Lee) 
 
 
A causative link between psychological stress and acne has long been postulated. 
When the activity of the hypothalamic-pituitary-adrenal (HPA) axis system is 
increased due to stress, it results to the secretion of various hormones, such as the 
melanocortins and glucocorticoids. It is well known that α-melanocyte stimulating 
hormone (α-MSH) causes lipogenesis in cultured human sebocytes. Although 
corticosteroids cause immunosuppressive and anti-inflammatory effects, it is 
clinically well known that systemic or topical glucocorticoid treatment aggravates an 
acneiform reaction. The 11β-hydroxysteroid dehydrogenase type 1 (HSD11β1) 
regenerates active glucocorticoids from inactive forms and plays a central role in 
regulating intracellular glucocorticoid concentration.  
First of all, the effect of α-MSH was investigated on the expression of its receptors, 
MC1R and MC5R, according to the differentiated status of sebocytes and the 
expression of pro-inflammatory cytokines and toll-like receptor (TLR) 2. 
Additionally, different effects of α-MSH on the lipogenesis were investigated. Second, 
it was investigated whether HSD11β1 is expressed in sebocytes and cytokines affect 
on the expression of HSD11β1. Similarly, whether HSD11β1 affects sebogenesis on 
sebocytes was also investigated.  
Consequently, MC5R was only observed in differentiated SZ95 sebocytes. Lipid 
droplets were increased by α-MSH in differentiated SZ95 sebocytes. Moreover, 
SREBP-1c mRNA was increased by α-MSH, and SREBP-1c mRNA was more 
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increased in differentiated SZ95 sebocytes. These results suggest that the sebotrophic 
effect of α-MSH in SZ95 sebocytes via MC5R is superior to that of the sebotrophic 
effect happening via MC1R. The IP3 receptor antagonist and the PLC inhibitor 
suppressed the expression of SREBP-1c mRNA which was induced by α-MSH in 
both undifferentiated and differentiated SZ95 sebocytes. These results indicate that α-
MSH induces sebogenesis in SZ95 sebocytes by induction of SREBP-1c via IP3/PLC 
pathway. The expression of HSD11β1 in SZ95 sebocytes was increased by 
dexamethasone. An increment of HSD11β1 expression was inhibited by RU-486, 
glucocorticoid receptor (GR) antagonist, PF-915275, HSD11β1 specific inhibitor, and 
pioglitazone, PPAR-γ agonist. Similarly, dexamethasone increased sebogenesis in 
SZ95 sebocytes. In addition, RU-486, PF-915275, and pioglitazone inhibited 
sebogenesis induced by dexamethasone in SZ95 sebocytes. Moreover, 
dexamethasone increased the expression of SREBP-1a and 1c mRNA. The increment 
of SREBP-1a and 1c mRNA expression was inhibited by RU486, PF-915275, and 
pioglitazone. These data demonstrate that HSD11β1 involves dexamethasone-induced 
lipid synthesis, which is induced by SREBP-1a and 1c via GR. α-MSH induced the 
gene expression level of pro-inflammatory cytokines, such as IL-1α, IL-6 and TNF-α 
in both undifferentiated and differentiated SZ95 sebocytes. IL-1α, IL-6 and TNF-α 
induced HSD11β1 gene expression level in SZ95 sebocytes and α-MSH induced 
TLR-2 gene expression in differentiated SZ95 sebocytes. Dexamethasone also 
induced TLR-2 gene expression in SZ95 sebocytes. These results suggest that α-MSH 
and dexamethasone may involve inflammatory and immune reaction in acne vulgaris 
lesions. 
To conclude, psychological stress induced α-MSH induced not only sebum 
secretion but also inflammation in acne vulgaris. Furthermore, the following findings 
suggest that receptors of α-MSH and HSD11β1 could be critical factors for the 
medical treatment of acne vulgaris.                     
 
---------------------------------------------------------------------------------------------------------- 
Key words : acne, sebogenesis, α-MSH, HSD11β1, TLR-2 
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I. INTRODUCTION 
Acne vulgaris is a disease that affects the infundibulum and sebaceous glands of 
the human pilosebaceous unit and of the gland itself. This condition develops 
during puberty, appearing usually at the site of acne prone lesions, mainly the chest, 
back, and face. Although it is not life-threatening, it can cause psychological stress 
and permanent scars. The earlier forms of acne are characterized by 
microcomedones. As the disease progresses into severity, comedogenesis and 
inflammation develop. Duct rupture is a late event in the development of most 
inflammatory lesions1-5. Pathogenesis of acne vulgaris that has so far been 
elucidated includes excessive sebum secretion, abnormal keratinization of 
follicular infundibulum, microbial overgrowth including Propionibacterium acnes, 
and perifollicular inflammation. In addition to these factors, psychological stress is 
also considered as an important pathophysiologic factor6.  
The possibility of a causative influence of emotional stress, especially of 
stressful life events, on the course of acne has long been postulated7,8. Chiu et al., 
in a prospective study of 22 university students, found that patients with acne may 
experience a worsening of their disease during examinations9. The endocrine 
mediators controlling the activity of hypothalamus-pituitary-adrenal (HPA) axis 
including the corticotropin-releasing hormone (CRH) and the proopiomelanocortin 
(POMC) peptides and their receptors, are known to be expressed in the skin and 
sebaceous gland6, 10-13. CRH, its binding protein (CRH-BP) and corticotropin 
receptors (CRH-Rs) act as a central regulatory system of the HPA axis11. Recent 
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studies have confirmed the presence of a complete CRH/CRH-BP/CRH-R system 
in human sebocytes. It was also confirmed that CRH directly induces lipid 
synthesis13-14. Melanocortins, the products of the POMC gene, include 
adrenocorticotropin hormone (ACTH), and α-, β- and γ-melanocyte stimulating 
hormone (MSH)15. MSHs derive their functions by binding and activating their 
respective receptors, which are termed as melanocortin receptor (MCR). Thus far, 
five MCRs—MC1R to MC5R—have been identified. In sebaceous glands and 
cultured human sebocytes, the expression of MC1R and MC5R was reported16-17. It 
was also reported that α-MSH treatment can induce lipogenesis in cultured human 
sebocytes18. Moreover, a recent study demonstrated that α-MSH in human 
sebocytes controls a key cellular signaling pathway—the calcium ion response—
which may coordinate MC1R-mediated sebum secretion19. 
Stress activates the HPA axis and the increased activity of the HPA axis results 
in the increase of corticosteroids, especially cortisol20. Endogenous glucocorticoids 
regulate a host of critical physiological functions, such as stress and inflammatory 
responses, cellular growth and differentiation, and a variety of metabolic 
processes21. Glucocorticoid action on target tissues depends not only on circulating 
levels but also on their intracellular concentration. Both active glucocorticoids 
(cortisol in human and corticosterone in rodents) and their inactive 11-keto forms 
(cortisone in human and 11- deoxycorticosterone) circulate in similar 
concentrations in blood22. The major fraction of active glucocorticoids exists as 
complex with binding proteins, cortisol binding protein (CBG) and albumin, and a 
small fraction is biologically active. Inactive forms circulate without binding 
proteins, which readily enter the cells where they are converted to active forms in a 
tissue-specific manner22. The 11β-hydroxysteroid dehydrogenase type 1 and 2 
(HSD11β1 and HSD11β2) are tissue-specific glucocorticoid deactivating enzyme. 
HSD11β1 functions predominantly as oxoreductase, which converts inactive 
cortisone into active cortisol23. Located in the endoplasmic reticulum membrane, it 
requires the cofactor NADPH for the oxoreductase activity24-25. It also functions as 
dehydrogenase, which converts cortisol into cortisone. HSD11β1 is widely 
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distributed in most tissues including the liver, adipose, skeletal muscles, vascular 
smooth muscles, brain, eye, synovium and bone26-33. HSD11β2 functions as a 
potent dehydrogenase. It is expressed in the kidney and in the colon34-35. It is well 
known that HSD11β1 is associated with the pathogenesis of many metabolic 
diseases33, 36-38. Recently, it was reported that HSD11β1 is located in keratinocytes 
and fibroblastes in humans, and in mouse skin39. It is demonstrated that 
glucocorticoid increases HSD11β1 mRNA expression in human fibroblastes39.  
Psychological stress induces a variety of neuropeptides and stress hormones. 
Some of these neuropeptides and hormones, including α-MSH and glucocorticoid, 
increase the lipogenesis of sebocytes. In this study, the mechanism of lipogenesis 
induced by α-MSH or glucocorticoid and the biological effects of α-MSH or 
glucocorticoid on sebocytes were investigated. 
Although it is well known that the human sebocyte is a direct cellular target of 
α-MSH, which appears to regulate lipogenesis, current knowledge about the exact 
mechanism involved in the regulation of lipogenesis by α-MSH and the biological 
effects of melanocortins on the human sebaceous gland besides lipogenesis is still 
incomplete. No report has yet been made on the effect of gluccorticoid on 
sebogenesis in sebocytes. Moreover, the effect of HSD11β1 on lipogenesis in 
sebocytes has not yet been investigated. This study investigated the effect of α-
MSH on the expression of its receptors, MC1R and MC5R, according to the 
differentiation status of sebocytes and the expression of proinflammatory cytokines 
and toll-like receptor (TLR) 2. This study also investigated the differential effect of 
α-MSH on lipogenesis. The expression of HSD11β1 on sebocytes and their 
regulation by cytokines were investigated as well. Further, this study investigated 
whether HSD11β1 affects sebogenesis in sebocytes. 
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II. MATERIALS AND METHODS 
 
1. Cell lines and cell culture 
 
Immortalized human sebocyte cell line SZ95, which expresses the major 
characteristics of normal sebocytes40 were maintained in Dubecco’s modified 
Eagle medium (DMEM)/F-12 containing 10% heat-inactivated fetal bovine 
serum, 2.5 mM glutamax I, 50 µg/ml gentamicin, 2.5 ng/ml human epidermal 
growth factor (hEGF) and 10 mM 4-(2-hydroxyethyl)-1-piperazineethane-
sulfonic acid (HEPES) (Gibco Invitrogen Corporation, Pasley, UK). Before 
the treatment of reagents, SZ95 sebocytes were maintained for 24 h in phenol 
red-free DMEM/F12 containing 50 µg/ml bovine pituitary extract, 1mg/ml 
fatty acid free bovine serum albumin, 2.5 mM glutamax I, 50 µg/ml 
gentamicin, 2.5 ng/ml hEGF and 10 mM HEPES. Cells were maintained in 
humidified atmosphere of 5% CO2 at 37℃ and medium was replaced every 
two days. 
 
2. Reagents  
 
α-MSH, 2-aminoethoxydipheryl borate (2-APB), u-73122, dexamethasone, 
RU486, and pioglitazone were purchased from Sigma Aldrich (Sigma Aldrich, 
St.Louis, MI, USA). To induce the differentiation of SZ95 sebocytes, 20 nM 
testosterone (Tokyo Chemical Industry Co., Ltd., Tokyo, Japan) and 100 µM 
linoleic acid (Sigma Aldrich) were simultaneously treated on SZ95 sebocytes 
for 24 h41.  
 
3. Immunofluorescent staining 
 
The cell were cultured in Lab-Tek 4-chamber slides (Nunc, Roskilde, 
Denmark) at a seeding density of 1x105 per well for two days before reagent 
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treatment. After reagent treatment, the wells were washed twice with PBS and 
fixed with 4% paraformaldehyde in PBS for 5 min. Then, the chamber slides 
were washed three times with PBS and 500 µl of 0.1% Triton X-100 in PBS 
was added to each well for 5 min for cell permeabilization. After washing with 
0.1% Triton X-100 in PBS, the cells were stained with the goat anti-MC1R 
antibody or goat anti-MC5R antibody (1:100 respectively, Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) in PBS with 30 mg/ml BSA for 30 min 
at 37℃. After rinsing in PBS, the cells were stained with a donkey anti-goat 
antibody conjugated with FITC (1:100 Santa Cruz Biotechnology) as a 
secondary antibody for 30 min at room temperature. After counterstaining with 
propidium iodide (1:100, Invitrogen Life Technologies, Carlsbad, CA, USA) 
for 3 min at room temperature, the slides were mounted in Vectashield (Vector 
Laboratories, Burlingame, CA, USA). Cells were examined and imaged with 
confocal microscope equipped with digital camera (Nikon ECLIPSE Ti, Nikon, 
Tokyo, Japan).  
 
4. Immunohistochemistry 
 
A 2 mm punch biopsy specimen was obtained from the acne lesional skin. 
Biopsy specimens from three patients were embedded in paraffin. Paraffin-
embedded punch biopsy tissues were cut into 4-µm sections. Deparaffinized 
paraffin sections were processed for rehydration and air dried. Later the 
sections were incubated with a peroxidase-blocking reagent for 10 min in 
order to prevent endogenous peroxidase activity. After blocking the non-
specific antibody binding by incubation with a serum free protein for 10 min at 
room temperature, the primary antibodies (1:100 dilution) of HSD11β1 
(Cayman Chemical, Ann Arbor, MI, USA) and GR (Cell Signaling 
Technology, INC., Danverse, MA, USA) were applied for 30 min at 37℃. 
Sections were then soaked with horseradish peroxidase (HRP)-conjugated 
secondary antibody for 30 min at room temperature. Staining for these 
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proteins was detected using NovaRed (Vector Laboratories) as a substrate. 
Between steps, the slides were rinsed for 10 min in 0.05 M Tri-HCl buffer 
with 0.01% Triton-X-100. All sections were lightly counterstained with 
hematoxylin.  
 
5. Measurement of lipid droplets in cytoplasm 
 
Detection of lipid contents was performed by Nile-red staining as previously 
described18-19. Briefly, SZ95 sebocytes were cultured in 96-well tissue culture 
plates at a seeding density of 2,500 cells per well for two days. After the 
treatment of reagents, the wells were washed with PBS, and 100 µl of a 10 
µg/ml nile red solution in PBS was added to each well. The plates were then 
incubated at 37  for 30℃  min and were read on a Fluostar Optima (BMG 
Labtechnologies Pty. Ltd, Australia). The results are presented as percentages 
of the absolute fluorescence units in comparison with the controls, using 485 
nm excitation and 565 nm emission filter for neutral lipids and 540 nm 
excitation and 620 nm emission filters for polar lipids. Experiments were 
carried out in triplicate. 
 
6. Oil-red O staining 
 
The detection of lipid contents in SZ95 sebocytes was performed by Oil-red O 
staining. SZ95 sebocytes were cultured in Lab-Tek 4-chamber slides (Nunc) at 
a seeding density of 1x105 per well for two days before reagent treatment. 
After the reagent treatment, the wells were washed twice with PBS and fixed 
with 4% paraformaldehyde in PBS for 5 min. Fixed cells were stained with the 
Oil red O solution, a mixture of 1% Oil red O (Sigma Aldrich) and dH2O in a 
ratio of 6:4 (vol/vol), for 15 min. These were then, washed with PBS. Stained 
cells were visualized by microscopy.  
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7. Real-time quantitative RT-PCR 
 
Total RNA was extracted from cells using TRIzol reagent (Invitrogen Life 
Technologies) and 1 µg of total RNA was converted to cDNA using TaKaRa 
RNA PCR Kit Ver.2.1 (TaKaRa BIO INC. Shiga, Japan), as following 
reaction condition : 45  for 45℃  min and 95  for 5℃  min. Gene expression 
signals were quantified with real-time PCR (TaqMan, Applied Biosystems, 
Foster City, CA, USA). Probes and primers were obtained from Applied 
Biosystems as Assays-on-Demand Gene Expression Assays (HSD11β1: 
Hs00194153_m1 and β-actin: TaqMan β-actin Control Reagents). Reactions 
were carried out on the ABI 7300 and relative transcript levels were 
determined using β-actin as a reference gene. The data were analyzed using of 
7300 system software (Applied Biosystems). Real-time PCR amplifications 
were performed using Express SYBR GreenER Supermix with Premixed 
ROX (Invitrogen Life Technologies) in an ABI 7300 (Applied Biosystems) 
following the manufacturer’s protocol. Gene-specific primers were designed 
by using Primer Blast of NCBI. The primers for β-actin, MC1R, MC5R, sterol 
response element-binding protein (SREBP)-1a and SREBP-1c are showed in 
Table 1. Reaction condition was as follows: initiated at 50  for 2 min, 95  ℃ ℃
for 10 min, followed by a cycling condition of 95  for 10 sec and 60  for 1 ℃ ℃
min for 40 cycles. The expression of β-actin was used as internal standard. 
The data were analyzed using of 7300 system software (Applied Biosystems). 
 
8. Western blot analysis 
 
Reagents-treated SZ95 sebocytes were washed with PBS. Then cells were 
lysed with RIPA buffer (GenDepot, barker, TX, USA) with proteinase 
inhibitor cocktail (Thermo Fisher Scientific Inc. Rockford, IL, USA) and 
centrifuged at 13200 rpm for 30 min at 4 . Supernatants were collected, and ℃
the protein concentration was measured with the use of a BCA Protein Assay 
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Reagent (Thermo Fisher Scientific Inc). After blocking with 5% skim milk, 
the blots were washed with TBS that contained 0.01% tween 20 (Amresco Inc. 
Branded Products Group, Cochran Solon, OH, USA) (0.01% TBS-T) and 
incubated with an appropriate primary antibody at 4  overnight. Antibodies ℃
against keratin 7 (Abcam plc, Cambridge, MA, USA), epithelial membrane 
antigen (EMA) (Abcam plc), and human β-actin (Santa Cruz Biotechnology) 
were used at 1:1000 dilution. After washing with 0.01% TBS-T three times, 
the membranes were incubated with HRP-conjugated secondary antibody 
(1:3000, Santa Cruz Biotechnology) for 1 h at room temperature and then 
washed again. The membranes were visualized with the use of ECL Plus 
Western Blotting Detection System (GE Healthcare, Amersham, UK). The 
images were recorded using JP-33 X-ray Filmprocessor (Jungwon Precision 
IND. Co., Ltd. Seoul, Korea). 
 
9. RNA interference 
 
Three HSD11β1-specific siRNAs (HSD11β1-siRNA-1, 2, 3 groups) and 
negative control (Scramble group) with no significant homology with human 
gene sequences were purchased from Invitrogen (Invitrogen Life 
Technologies). Cells were seeded at a density of 5 x 104 into a six-well plate 
24 h before transfection, resulting in approximately 50% confluency. In each 
well, 50 nM HSD11β1-siRNA-1, 2, 3 or scramble and 5 µl Lipofectamine 
RNAiMAX (Invitrogen Life Technologies) were added to 250 µl Opti-MEM 
(Invitrogen Life Technologies), mixed gently and then added to the plates. The 
plate was incubated for 48 h at 37℃ until it was ready for further assay.  
 
10. Statistical analysis 
 
The results are expressed as means ± standard deviation (S.D.). P values less 
than 0.05 were considered as statistically significant. On-way ANOVA with 
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Dunnett’s post test was performed using GraphPad InStat version 3.00 for 
Windows 95 (GraphPad Software, San Diego, CA, USA, www.graphpad.com) 
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Table 1. Primer sequences for various human genes for the real-time quantitative  
PCR 
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III. RESULTS 
 
1. Differentiation of cultured sebocytes SZ95 was induced by testosterone  
and linoleic acid co-treatment. 
 
In order to examine the differentiation status of cultured sebocyte, the 
expression of cytokeratin 7 and EMA were observed through Western blotting 
as markers for undifferentiated and differentiated sebocytes42, respectively. 
The induction of sebocyte differentiation by simultaneous treatment with 
testosterone (20 nM) and linoleic acid (100 µM) (T/LA)41 showed significant 
increase in EMA expression but no significant difference in cytokeratin 7 
expression (Figure 1). These results suggest that T/LA induces the 
differentiation of cultured SZ95 sebocytes. 
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Figure 1. EMA expression was increased by testosterone and linoleic acid 
co-treatment. The expression of proliferation or differentiation markers in 
sebocytes in response to α-MSH was analyzed by Western blotting analysis. 
Expression of cytokeratin 7, a marker for proliferating sebocytes was not 
changed. However, the marker for differentiated sebocytes—epithelial 
membrane antigen (EMA) expression—was increased by T/LA.  
T/LA : testosterone and linoleic acid co-treatment 
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2. α-MSH-induced MC1R and MC5R expression in sebocytes was dependent  
on the differentiation status. 
 
Previously, it was reported that MC1R is constitutively expressed in 
sebocytes, irrespective of its differentiation status. The MC5R expression was 
affected by differentiation status41. In order to investigate the effects of α-
MSH on the expression of both receptors, 0.1 µM of α-MSH was treated on 
either undifferentiated or T/LA treated sebocytes. Similar to the previous 
results, T/LA treatment did not affect the protein expression of MC1R but 
increased the expression of MC5R along with sebocyte differentiation (Figure 
2). When α-MSH alone was treated to SZ95 sebocytes, MC1R expression was 
increased while MC5R expression remained the same (Figure 2, Figure 3 A). 
In contrast, sequential treatment of α-MSH after T/LA treatment showed 
increments of MC5R expression but not MC1R expression (Figure 2, Figure 3 
B).  
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Figure 2. Effects of α-MSH treatment on expression of MC1R and MC5R 
in SZ95 sebocytes SZ95 sebocytes were fixed and then stained with MC1R or 
MC5R as described in the text. MC1R was detected in untreated SZ95 
sebocytes (A). α-MSH induced the increase of MC1R expression in the 
undifferentiated SZ95 sebocytes (B). However, T/LA did not affect MC1R 
expression in T/LA-treated SZ95 sebocytes (C). In addition, α-MSH did not 
affect expression of MC1R in T/LA-treated SZ95 sebocytes (D). MC5R was 
not detected in untreated SZ95 sebocytes (E). Similarly, α-MSH did not 
induce the expression of MC5R in the undifferentiated SZ95 sebocytes (F). On 
the other hand, T/LA induced MC5R expression in T/LA-treated SZ95 
sebocytes (G). Interestingly, α-MSH significantly increased MC5R expression 
in the T/LA-induced differentiated SZ95 cells (H).  
T/LA : testosterone and linoleic acid co-treatment 
 
 
 
 
 
 
17 
 
 
Figure 3. Effects of α-MSH treatment on mRNA expression of MC1R and 
MC5R in SZ95 sebocytes While α-MSH treatment significantly increased the 
18 
expression of MC1R in the undifferentiated SZ95 sebocytes (A), increase of 
MC5R mRNA was observed in T/LA induced differentiated SZ95 cells (B).  
T/LA : testosterone and linoleic acid co-treatment, *: p<0.05  
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3. α-MSH induced lipid droplets in cytoplasm of SZ95 sebocytes.  
 
In order to examine the lipogenetic effects of α-MSH on cultured sebocytes, 
nile red staining was performed. In undifferentiated SZ95 ssebocytes, nile red 
stained lipid droplets in the cytoplasm was not detected (Fgiure 4 A). While a 
slight increase of lipid droplets was detected in α-MSH treated cells, the 
increment was not so significant, compared to the T/LA treated cells (Figure 4 
B).Along with the differentiation, T/LA treatment also significantly increased 
the number of nile red stained lipid droplets in the cytoplasm of sebocytes 
(Figure 4 C). Moreover, during the sequential treatment of α-MSH following 
T/LA, the significant increase of lipid droplets was observed (Figure 4 D). The 
combination of testosterone and linoleic acid showed synergistic effect on the 
amplification of polar and neutral lipids (Figure 4 E and F). α-MSH increased 
polar and neutral lipids in undifferentiated and differentiated SZ95 sebocytes 
(Figure 4 E and F). 
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Figure 4. α-MSH induced lipid droplets in SZ95 sebocytes. The effect of α-
MSH on the lipogenesis of sebocytes with or without pre-treatment with T/LA 
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Nile red staining showed a slight increase in cytosolic lipid accumulation in 
undifferentiated SZ95 sebocytes (A and B) by α-MSH treatment. T/LA 
treatment induced significant increase in lipogenesis. Moreover, α-MSH 
treatment further increased the lipid contents in SZ95 sebocytes which were 
pre-treated with T/LA (C and D). The production of polar (E) and neutral (F) 
are shown. Polar and neutral lipid was increased by α-MSH in SZ95 sebocytes 
treated with T/LA or in SZ95 sebocytes untreated with T/LA (E and F). T/LA 
exhibited a synergistic effect on polar and neutral lipids (E and F).   
T/LA : testosterone and linoleic acid co-treatment, *: p<0.05, **: P<0.01 
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4. α-MSH increased SREBP-1c mRNA expression in SZ95 sebocytes but  
did not affect the mRNA expression of SREBP-1a. 
 
To examine whether the increased lipid synthesis by α-MSH is related with 
the regulation of SREBP-1 gene expression, SREBP-1 gene expression was 
analyzed through real-time quantitative PCR. There were no significant 
changes in the SREBP-1a mRNA expression level in the sebocytes that were 
treated with α-MSH with or without pre-treatment with T/LA (Figure 5 A). On 
the other hand, α-MSH significantly increased the SREBP-1c mRNA level in 
both undifferentiated and differentiated SZ95 sebocytes (Figure 5 B). In 
addition, the SREBP-1c mRNA level in differentiated SZ95 sebocytes was 
more increased than in undifferentiated SZ95 sebocytes by α-MSH (Figure 5 
B).  
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Figure 5. α-MSH induced SREBP-1c mRNA expression level in SZ95 
sebocytes. α-MSH did not affect expression of SREBP-1a mRNA in T/LA-
24 
untreated and –treated SZ95 sebocytes (A). However, SREBP-1c mRNA 
expression level was increased by α-MSH in T/LA-untreated SZ95 sebocytes 
(B). In T/LA-treated SZ95 sebocytes, the SREBP-1c mRNA expression level 
was more increased compared to the α-MSH that was treated in SZ95 
sebocytes (B). Moreover, when 0.1 µM α-MSH was treated in T/LA-treated 
SZ95 sebocytes, the SREBP-1c mRNA expression level increased 
significantly (B).  
T/LA : testosterone and linoleic acid co-treatment, *: p<0.05, **: P<0.01 
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5. IP3 and PLC inhibitors inhibited the upregulation of SREBP-1c mRNA  
expression induced by α-MSH in both undifferentiated and differentiated 
SZ95 sebocytes.   
 
Recently, it was demonstrated that α-MSH increased the intracellular calcium 
level of SZ95 sebocytes and that α-MSH-mediated calcium mobilization 
originated from calcium stores and was mediated by inositol triphosphate19. 
Moreover, α-MSH increased the MC1R immunoreactivity and lipid synthesis 
in SZ95 sebocytes in the presence of testosterone19. To examine whether α-
MSH-mediated calcium mobilization affects lipid synthesis in SZ95 sebocytes, 
SREBP-1c mRNA expression in SZ95 sebocytes was detected using real-time 
quantitative PCR. 2-APB, an IP3 receptor antagonist, inhibited α-MSH 
induced SREBP-1c mRNA increase in both undifferentiated and differentiated 
SZ95 sebocytes (Figure 6 A and B). Moreover, PLC inhibitor u-73122 
prevented α-MSH induced SREBP-1c mRNA increase in both undifferentiated 
and differentiated SZ95 sebocytes (Figure 6 A and B).  
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Figure 6. 2-APB and u-73122 inhibited SREBP-1c mRNA expression level 
27 
induced by α-MSH in both undifferentiated and differentiated SZ95 
sebocytes. 75 µM 2-APB and 10 µM u-73122 inhibited the increment of 
SREBP-1c mRNA expression by α-MSH in undifferentiated SZ95 sebocytes 
(A). Similarly, 2-APB and u-73122 prevented α-MSH-induced SREBP-1c 
mRNA expression in differentiated SZ95 sebocytes (B).  
T/LA : testosterone and linoleic acid co-treatment , **: P<0.01, *** : P < 
0.001 
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6. HSD11β1 expression in sebaceous glands of acne vulgaris 
 
The expression of HSD11β1 in the sebaceous glands of the lesional skin of 
patients with acne, sebaceous hyperplasia and folliculitis was observed 
through the immunohistochemical study. HSD11β1 expression was detected in 
the human sebaceous glands (Figure 7). The sebaceous glands in the lesional 
skin of acne showed increased immunoreactivity of HSD11β1 compared to 
those in the skin from sebaceous hyperplasia and folliculitis (Figure 7).   
 
 
Figure 7. Expression of HSD11β1 in acne vulgaris was increased. 
HSD11β1 expression in sebaceous glands was confirmed by 
immunohistochemical staining. HSD11β1 was highly expressed in sebaceous 
gland in acne vulgaris. (A) Acne vulgaris (B) Sebaceous hyperplasia (C) 
Folliculitis (original magnification x40, inlet box: x400) 
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7. Dexamethasone increased HSD11β1 mRNA expression in SZ95 sebocytes. 
 
To examine whether dexamethasone affects the expression of HSD11β1, real-
time quantitative PCR was used. The HSD11β1 mRNA level was increased by 
dexamethasone in SZ95 sebocytes (Figure 8). The RU486 inhibited expression 
of HSD11β1 mRNA was also increased by dexamethasone (Figure 8).  
 
 
Figure 8. GR antagonist, RU-486, inhibited the upregulation of HSD11β1 
mRNA expression by dexamethasone in SZ95 sebocytes. 1 µM 
dexamethasone increased HSD11β1 mRNA expression in SZ95 sebocytes. 1 
µM RU-486 inhibited the increment of HSD11β1 mRNA expression by 
dexamethasone.  
Dexa : dexamethasone, *: P < 0.05, **: P < 0.01. 
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8. Dexamethasone increased lipid droplets in cytoplasm of SZ95 sebocytes. 
 
To examine the lipogenetic effects of dexamethasone on SZ95 sebocytes, 
Oil-red O staining was performed. When SZ95 sebocytes was treated with 1 
µM dexamethasone, lipid droplets were increased in the cytoplasm of 
sebocytes than un-treated SZ95 sebocytes (control) (Figure 9 A and B). 
However, when SZ95 sebocytes were co-treated with GR antagonist RU-486 
and dexamethasone, lipid droplets were not increased (Figure 9 B and C). This 
results accordance with previous report which has demonstrated that 
dexamethasone increased lipid droplets in SZ95 sebocytes via GR. 
Dexamethasone increased significantly polar and neutral lipids (Figure 9 E 
and F). The co-treatment of RU-486 and dexamethasone exhibited inhibition 
of polar lipids and neutral lipids (Figure 9 E and F).  
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Figure 9. Dexamethasone increased lipid droplets in SZ95 sebocytes. 
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Dexamethasone increased lipid droplets in SZ95 sebocytes (B). RU-486 
decreased lipid droplets that were increased by dexamethasone (C). The 
production of polar and neutral lipids was increased by dexamethasone (D and 
E). RU-486 inhibited the polar and neutral lipids that were increased by 
dexamethasone (D and E).  
Dexa : dexamethasone, *: P < 0.05, **: P < 0.01. 
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9. Dexamethasone increased SREBP-1a and 1c mRNA expression in SZ95  
sebocytes. 
 
To examine whether the increase of lipids by dexamethasone is related with 
SREBP-1 gene expression, SREBP-1 gene expression was detected using real-
time quantitative PCR. After treatment with dexamethasone, the SREBP-1a 
and SREBP-1c mRNA level in SZ95 sebocytes were increased (Figure 10 A 
and B). Moreover, the increment of SREBP-1a and 1c mRNA expression was 
inhibited by RU-486 (Figure 10 A and B). 
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Figure 10. RU-486 inhibited the upregulation of SREBP-1a and 1c mRNA 
expression by dexamethasone in SZ95 sebocytes. 1 µM dexamethasone 
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increased SREBP-1a and -1c mRNA expression in SZ95 sebocytes (A and B). 
1 µM RU-486 inhibited the increment of SREBP-1a and 1c mRNA expression 
by dexamethasone (A and B). 
Dexa : dexamethasone, *: P < 0.05, **: P < 0.01  
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10. PPAR-γ agoinst and specific inhibitor of HSD11β1 inhibited the  
dexamethasone-induced HSD11β1 mRNA expression in SZ95 sebocytes. 
 
It is well known that PPAR-γ agonists inhibit the expression of HSD11Β1 in 
adipose tissues and adipocytes43. Moreover, it is known that PPAR-γ agonist 
pioglitazone does not affect lipid synthesis in human sebocytes44. To examine 
whether pioglitazone affects the mRNA expression of HSD11β1 in SZ95 
sebocytes, HSD11β1 gene expression was detected using real-time 
quantitative PCR. Pioglitazone inhibited the expression of HSD11β1 mRNA, 
which was increased by dexamethasone (Figure 11). Similarly, PF-915275, a 
specific inhibitor of HSD11β1, inhibited the expression of HSD11β1 mRNA 
(Figure 11). However, pioglitazone and PF-915275 co-treatment did not show 
synergistic effects on HSD11β1 inhibition. 
 
 
Figure 11. Pioglitazone and PF-915275 inhibited the upregulation of 
HSD11β1 mRNA expression by dexamethasone in SZ95 sebocytes. 1 µM 
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pioglitazone and 1 µM PF-915275 inhibited the increments of HSD11β1 
mRNA expression, which was increased by dexamethasone. Co-treatment of 
pioglitazone and PF-915275 also prevented HSD11β1 mRNA to be induced 
by dexamethasone but did not show synergistic effects on HSD11β1 inhibition. 
Dexa : dexamethasone, Piog. : pioglitazone, PF : PF-915275, Piog.+PF : co-
treatment of pioglitazone and PF-915275, *: P < 0.05, **: P < 0.01 
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11. Pioglitazone and PF-915275 inhibited the lipid synthesis of SZ95  
sebocytes treated with dexamethasone. 
 
To examine the lipogenetic effects of pioglitazone and PF-915275 on SZ95 
sebocytes treated with dexamethasone, Oil-red O staining was performed. 
When 1 µM dexamethasone was treated to SZ95 sebocytes, lipid droplets were 
increased as compared to untreated SZ95 sebocytes (control) (Figure 12 A and 
B). However, when dexamethasone and pioglitazone, PPAR-γ agonist, or PF-
915275, specific inhibitor of HSD11β1 were co-treated to SZ95 sebocytes, 
lipid droplets were not increased (Figure 12 B and C or D). Polar and neutral 
lipids increased by dexamethasone in SZ95 sebocytes (Figure 12 E and F). 
Co-treatment of pioglitazone and dexamethasone exhibited inhibition of polar 
lipids not neutral lipids (Figure 12 E and F). On the other hand, co-treatment 
of PF-915275 and dexamethasone exhibited inhibition of neutral lipids not 
polar lipids (Figure 12 E and F).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
39 
 
 
 
Figure 12. Pioglitazone and PF-915275 inhibited the upregulation of lipid 
droplets by dexamethasone in SZ95 sebocytes. Dexamethasone increased 
the lipid droplets in SZ95 sebocytes (A and B). Pioglitazone and PF-915275 
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reduced the lipid droplets induced by dexamethasone in SZ95 sebocytes (C 
and D). Arrows represent the lipid droplet stained by Oil red O. The 
production of polar and neutral lipids was increased by dexamethasone (E and 
F). Pioglitazone inhibited the polar lipids that were increased by 
dexamethasone (E). PF-915275 reduced the neutral lipids increased by 
dexamethasone (F).  
Dexa: dexamethasone, Piog. : pioglitazone, PF : PF-915275, **: P < 0.01, ***: 
P < 0.001 (original magnification x200, inlet box: x400)  
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12. HSD11β1 inhibitors abolished the dexamethasone effect on the SREBP- 
   1a and 1c expression in SZ95 sebocytes. 
 
After treatment with dexamethasone, the SREBP-1a and SREBP-1c mRNA 
level were increased in SZ95 sebocytes. Pioglitazone inhibited the SREBP-1a 
mRNA but not the SREBP-1c mRNA, which were increased by 
dexamethasone (Figure 13 A and B). On the other hand, PF-915275 inhibited 
the SREBP-1a and 1c mRNA that were increased by dexamethasone (Figure 
13 A and B).   
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Figure 13. Pioglitazone and PF-915275 inhibited the upregulation of 
SREBP-1a and 1c mRNA expression by dexamethasone in SZ95 sebocytes. 
Pioglitazone inhibited the SREBP-1a mRNA expression induced by 
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dexamethasone in SZ95 sebocytes (A). SREBP-1a and 1c mRNA expression 
that were increased by dexamethasone were prevented by PF-915275 in SZ95 
sebocytes (B and C).  
Dexa : dexamethasone, Piog. : pioglitazone, PF : PF-915275, **: P < 0.01, ***: 
P < 0.001  
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13. Dexamethasone did not affect SREBP-1a and 1c expression in SZ95  
sebocytes transfected with the HSD11β1-direct siRNA.  
 
To confirm the effect of pioglitazone and PF-915275, the HSD11β1-directed 
siRNA pools and the negative control pool were transfected to SZ95 sebocytes. 
HSD11β1 mRNA expression was not detected in the SZ95 sebocytes that were 
transfected with HSD11β1-direct siRNA pools (Figure 14 A). Similarly, 
dexamethasone did not affect the HSD11β1 mRNA expression level in the 
SZ95 sebocytes transfected with HSD11β1-direct siRNA pools. The negative 
control pool did not affect the SZ95 sebocytes. Likewise, dexamethasone did 
not affect to the SREBP-1a and 1c mRNA expression in the SZ95 sebocytes 
that were transfected with HSD11β1-direct siRNA pools (Figure 14 B and C).  
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Figure 14. Dexamethasone did not affect SREBP-1a and 1c expression in 
SZ95 sebocytes transfected with the HSD11β1-direct siRNA. Expression 
analysis of the HSD11β1 gene in the SZ95 sebocytes was done by PCR. 
HSD11β1 expression in SZ95 sebocytes that were transfected SC siRNA pools 
was increased by dexamethasone (A). Co-treatment of RU-486 and 
dexamethasone inhibited HSD11β1 expression in SC siRNA pools transfected 
SZ95 sebocytes (A). On the other hand, dexamethasone did not affect the 
expression of HSD11β1 in SZ95 sebocytes that were transfected with 
HSD11β1-directed siRNA pools (A). Similarly, dexamethasone did not affect 
the expression of SREBP-1a and 1c mRNA in SZ95 sebocytes that were 
transfected with HSD11β1-directed siRNA pools (B and C).  
Dexa : dexamethasone, SC siRNA : scramble siRNA, *: P < 0.05, **: P < 0.01  
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14. α-MSH induced mRNA expression of proinflammatory cytokines in  
SZ95 sebocytes. 
 
To examine the expression of proinflammatory cytokines in SZ95 sebocytes 
that were treated with α-MSH, real-time quantitative PCR was performed. 0.1 
µM α-MSH significantly increased the gene expression of proinflammatory 
cytokines including IL-1α, IL-6 and TNF-α in the SZ95 sebocytes (Figure 15 
A). Similarly, 0.1 µM α-MSH also increased IL-1α, IL-6 and TNF-α gene 
expression in the differentiated SZ95 sebocytes (Figure 15 B).  
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Figure 15. IL-1α, IL-6 and TNF-α mRNA expression were induced by α-
MSH in undifferentiated and differentiated SZ95 sebocytes. IL-1α, IL-6 
and TNF-α mRNA expression were determined in undifferentiated and 
differentiated SZ95 sebocytes after α-MSH treatment using real-time 
quantitative PCR (A and B). α-MSH induced mRNA expression level of IL-1α, 
IL-6 and TNF-α in undifferentiated and differentiated SZ95 sebocytes (A and 
B).  
T/LA : testosterone and linoleic acid co-treatment, **: P < 0.01  
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15. α-MSH induced TLR-2 gene expression in the differentiated SZ95  
sebocytes via MC5R. 
 
To investigate the expression of toll-like receptor-2 (TLR-2) in SZ95 
sebocytes treated with α-MSH, real-time quantitative PCR was performed. 
When 0.1 µM α-MSH treated to undifferentiated SZ95 sebocytes, gene 
expression of TLR-2 was decreased as compared to that of the untreated SZ95 
sebocytes (Figure 16 A). On the other hand, 0.1 µM α-MSH increased TLR-2 
gene expression in the differentiated SZ95 sebocytes (Figure 16 B).  
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Figure 16. TLR-2 gene expression induced by α-MSH was only detected in 
differentiated SZ95 sebocytes. α-MSH decreased TLR-2 gene expression in 
undifferentiated SZ95 sebocytes (A). However, TLR-2 gene was increased by 
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α-MSH in differentiated SZ95 sebocytes (B).  
T/LA : testosterone and linoleic acid co-treatment, * : P < 0.05  
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16. Proinflammatory cytokines increased HSD11β1 mRNA expression in  
SZ95 sebocytes. 
 
After treatment with proinflammatory cytokines, the HSD11β1 mRNA level 
was increased by IL-1α, IL-6 and TNF-α in SZ95 sebocytes (Figure 17). 
However, IL-8 did not affect the expression of HSD11β1 mRNA expression in 
SZ95 sebocytes (Figure 17).   
 
 
Figure 17. IL-1α, IL-6 and TNF-α but not IL-8 increased HSD11β1 mRNA 
expression level. Dexamethasone increased HSD11β1 mRNA expression in 
SZ95 sebocytes. Similarly, IL-1α, IL-6 and TNF-α induced HSD11β1 gene in 
SZ95 sebocytes but IL-6 did not induce HSD11β1 gene in SZ95 sebocytes. 
Dexa : dexamethasone, * : P < 0.05, ** : P < 0.01, *** : P < 0.001  
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17. TNF-α and dexamethasone increased TLR-2 gene expression in SZ95 
sebocytes. 
 
M Shibata (2009) found that two glucocorticoids, dexamethasone and 
cortisol, increased TLR-2 gene expression in cultured human keratinocytes 
without additional stimulation45. Moreover, glucocorticoids markedly 
enhanced TLR-2 gene expression in keratinocytes that had been stimulated 
with P. acnes or the inflammatory cytokines, TNF-α and IL-1α45.  
Therefore, to investigate the expression of TLR-2 in SZ95 sebocytes that were 
treated with dexamethasone, real-time quantitative PCR was performed. When 
1 µM dexamethasone was applied as treatment to SZ95 sebocytes, the gene 
expression of TLR-2 was induced (Figure 18). In addition, RU-486, 
pioglitazone, and PF-915275 completely inhibited the induced TLR-2 gene 
expression by dexamethasone (Figure 18). Several inhibitors and activators of 
the mitogen-activated protein kinase (MAPK) were used to elucidate the 
mechanism underlying the enhancement of TLR-2 gene expression by 
dexamethasone in SZ95 sebocytes. Ro-31-8220, an inhibitor of MAPK 
phosphatase-1 (MAPK-1), inhibited the increment of TLR-2 gene expression 
by dexamethasone in SZ95 sebocytes (Figure 18). Anisomycin, an activator of 
p38 MAPK, also inhibited the increase in TLR-2 gene expression generated by 
the dexamethasone. On the other hand, the p38 MAPK inhibitor, SB202190, 
did not inhibit the increase in TLR-2 gene expression induced by 
dexamethasone (Figure 18).  
Interestingly, TLR-2 gene expression was most increased by dexamethasone 
in SZ95 sebocytes that were stimulated with TNF-α (Figure 19).  
The increment of TLR-2 gene expression in SZ95 sebocytes treated with 
dexamethasone and TNF-α was also inhibited by RO-31-8220 and anisomycin 
(Figure 19).    
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Figure 18. TLR-2 gene expression induced by dexamethasone was 
inhibited by RU-486, inhibitors of HSD11β1 and inhibitors of p38 MAPK. 
Dexamethasone increased TLR-2 gene expression in SZ95 sebocytes. RU-486 
inhibited TLR-2 gene induction in dexamethasone treated SZ95 sebocytes. 
Also, TLR-2 gene induction was inhibited by pioglitazone, Ro31-8220 and 
anisomycin in dexamethasone treated SZ95 sebocytes. SB202190 did not 
inhibit the TLR-2 gene increased by dexamethasone in SZ95 sebocytes.    
Dexa: dexamethasone, Pio: pioglitazone, PF: PF-915275, RO: Ro31-8220, SB: 
SB202190, Aniso: Anisomycin, *: P < 0.05, ***: P < 0.001  
 
 
55 
 
Figure 19. Dexamethasone induced TLR-2 gene expression in SZ95 
sebocytes treated with TNF-α. TLR-2 gene expression was most increased 
by dexamethasone in SZ95 sebocytes that were stimulated with TNF-α. The 
induction of TLR-2 gene expression in SZ95 sebocytes treated with 
dexamethasone and TNF-α was also inhibited by RO-31-8220 and anisomycin. 
Dexa: dexamethasone, RO: Ro31-8220, SB: SB202190, Aniso: Anisomycin, 
**: P < 0.01, ***: P < 0.001  
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IV. DISCUSSION 
In sebaceous glands and cultured human sebocytes, the expression of MC1R and 
MC5R was reported16-17, 43. Previously, it was reported that the expressions of 
these receptors were dependent on the differentiation status of sebocytes. While 
MC1R is constitutively expressed, MC5R expression is observed only in the 
differentiated sebocytes43-44. In line with previous reports, our result showed that 
MC5R was only detected on the differentiated SZ95 sebocytes induced by 
testosterone and linoleic acid. In this result, α-MSH increased only MC1R 
expression in undifferentiated SZ95 sebocytes and only MC5R expression in 
differentiated SZ95 sebocytes. These results suggest that in the undifferentiated 
SZ95 sebocytes, α-MSH mainly upregulates MC1R expression while in 
differentiated SZ95 sebocytes, α-MSH mainly upregulates MC5R expression. It 
was also observed that the effect of α-MSH on the lipogenesis of sebocytes was 
greater in the T/LA-induced differentiated sebocytes than in the undifferentiated 
cells. Based on these observations, these results suggest that the sebotrophic effect 
of α-MSH in SZ95 sebocytes via MC5R is superior to that of the sebotrophic 
effect happening via MC1R.     
MCRs are seven-transmembrane G-protein coupled receptors that stimulate the 
cyclic adenosine monophosphate (cAMP) upon activation47. The MCRs-mediated 
intracellular signaling of α-MSH include the activation of adenylate cyclases that 
activates cAMP/PKA pathway, p38/MAP kinase pathway48, activation of the 
signal transducer and activator of transcription (STAT)1 transcription factor49, 
activation of PKC50 and elevation of intracellular calcium51. The α-MSH-
stimulated intracellular calcium ion concentration ([Ca2+]i) increase has been 
found in HEK 293 cells that were transfected with mouse MC5R52-53. It had been 
shown that MC peptides were able to modulate intracellular levels of calcium in 
normal human keratinocytes and HaCaT keratinocytes54. In a recent study, it was 
shown that α-MSH stimulation in SZ95 sebocytes via MC1R induces [Ca2+]i 
elevation via the activation of PLC/IP3/PKC pathways19. However, in that study, it 
was not investigated whether α-MSH/MC1R-mediated calcium signaling directly 
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regulates lipogenesis of SZ95 sebocytes.  
SREBPs which belong to the family of transcription factors is known to regulate 
the transcriptional activation of various genes required for endogenous cholesterol, 
fatty acid (FA), triacylglycerol and phospholipid synthesis55. Currently, three 
SREBP isoforms—SREBP-1a, SREBP-1c, and SREBP2—have been identified 
and their different roles in lipid synthesis have been reported. SREBP-1c is 
involved in FA synthesis and insulin induced glucose metabolism. SREBP-2 is 
comparatively specific to cholesterol synthesis while SREBP-1a seems to be 
involved in both pathways56. In the presence of sterol, complexes of SREBP and 
SREBP-cleavage-activating protein (SCAP) reside in the endoplasmic reticulum 
(ER)55. However, in the absence of sterols, the SREBP-SCAP complex is free and 
travels to the Golgi apparatus to be processed55. Previously, it was reported that 
SREBP-1 regulated lipogenesis in the immortalized human sebocytes SEB-1, 
which is induced by insulin growth factor-157. In this study, to investigate the 
effect of calcium signaling induced by α-MSH on lipogenesis of SZ95 sebocytes, 
SREBP-1 gene expression was observed. Based on the results, SREBP-1c was 
increased by α-MSH in undifferentiated and differentiated SZ95 sebocytes. 
Interestingly, in the differentiated SZ95 sebocytes, SREBP-1c mRNA expression 
was more increased than in undifferentiated SZ95 sebocytes. Moreover, SREBP-
1c mRNA expression induced by α-MSH was inhibited by 2-APB and u-73122 in 
both SZ95 sebocytes. These results suggest that α-MSH induces lipid synthesis in 
SZ95 sebocytes by induction of SREBP-1c via the IP3/PLC pathway.  
Psychological stress can induce or exacerbate various skin disorders which are 
associated with abnormal permeability barrier function, including psoriasis and 
atopic dermatitis58-60. The secretion of glucocorticoids (GCs) is a classic endocrine 
response to stress. Excess GC from either an endogenous or exogenous source can 
result to abnormalities in epidermal structure and function60. It is well known that 
systemic administration of RU-486, GR antagonist, or antalarmin, inhibitor of 
CRH, can improve skin disorder induced by psychological stress61-62. In addition, 
since glucocorticoids antagonize the action of insulin and induce insulin resistance 
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when the amount is in excess, the pharmacological inhibition of HSD11β1 has 
been suggested to be a very attractive therapy for insulin resistance and other 
metabolic disorders such as type 2 diabetes, obesity and Cushing's syndrome37-38, 63. 
In this study, dexamethasone, a glucocorticoid, increased lipid droplets and 
HSD11β1 expression in SZ95 sebocytes. Moreover, RU-486 inhibited lipid 
synthesis and HSD11β1 expression induced by dexamethasone. These results 
indicate that the increase of HSD11β1 by dexamethasone via GR in SZ95 
sebocytes enhances lipid synthesis in SZ95 sebocytes through augmentation of the 
GC reactivation. Furthermore, dexamethasone increased SREBP-1a and 1c gene 
expression in SZ95 sebocytes and the increment of SREBP-1a and 1c gene 
expression was inhibited RU-486. These results suggest that SREBP-1a and 1c 
involves lipid synthesis in SZ95 sebocytes by dexamethasone. 
Peroxisome proliferator-related receptors (PPARs) are a subfamily of former 
‘orphan receptors’ within the non-steroid receptor family of nuclear hormone 
receptors64. There are three subtypes (α,γ,δ); rat and human PPARδ are 
homologous to xPPARβ65-67. The finding, which states that PPARs have the 
potential to modulate lipogenesis, opens a new perspective on sebocyte 
pathophysiology 44, 68-70. However, the distinct effect of PPAR isoforms on 
lipogenesis is not yet clear 44, 69-71. The sebotrophic effect of PPARs is dependent 
on PPARs ligands44. M. Schuster, C.C et al., suggested that the sebostatic effect of 
PPARs not on the level of lipogenesis but by protecting cells from apoptosis and 
holocrine secretion72. It is well known that PPAR α and PPAR γ ligands reduce 
HSD11β1 activity and expression. Currently, PPARs are attractive therapeutic 
targets for antidiabetic therapy73-75. In this study, PPAR-γ agonist, pioglitazone, 
inhibited HSD11β1 expression and decreased the HSD11β1 expression increased 
by dexamethasone. Furthermore, pioglitazone alone did not induce lipid droplets 
in SZ95 sebocytes and inhibited increment of lipid droplets in the SZ95 sebocytes 
induced by dexamethasone. Based on results, PF-915275, a specific inhibitor of 
HSD11β inhibitor inhibited HSD11β1 gene expression, lipid droplets and SREBP-
1 gene expression induced by dexamethasone. The present data suggest that 
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HSD11β1 involves lipid synthesis in SZ95 sebocytes; therefore, inhibitors of 
HSD11β1 including PPAR-γ agonist might have beneficial effects on sebum 
secretion by inhibiting the sebaceous lipogenesis. 
In this study, α-MSH induced proinflammatory cytokines such as IL-1α, IL-6, 
and TNF-α, in undifferentiated and differentiated SZ95 sebocytes. Interestingly, in 
both SZ95 seobyctes, TNF-α mRNA expression was most increased by α-MSH. A 
number of proinflammatory cytokines, including IL-1α, IL-1β, IL-8, GM-CSF, 
and TNF-α, have been implicated in the inflammatory process of acne76-78. TNF-α, 
in particular, is regarded as a crucial cytokine in acne inflammation by involving a 
coordinated expression of adhesion molecules79-81. These results suggest that α-
MSH contribute to the upregulation of IL-1α, IL-6, and TNF-α via MC1R and 
MC5R activation, thereby leading to the comedo formation, neutrophil infiltration, 
and sustained inflammation in the acne pathogenesis. Moreover, it is well known 
that inflammatory cytokines, such as IL-1β and TNF-α, induce HSD11β1 gene 
expression in adipocytes22. In present experiments, which use SZ95 sebocytes, it 
was found that the IL-1α, IL-6, and TNF-α increased HSD11β1 gene expression. 
These data suggest that proinflammatory cytokines contribute to the augmentation 
of GC reactivation.  
It was also found through this study that α-MSH enhanced TLR-2 gene 
expression in differentiated SZ95 sebocytes. These data suggests that α-MSH may 
involve inflammatory and immune reactions in acne vulgaris lesions. Furthermore, 
dexamethasone remarkably enhanced TLR-2 gene expression in SZ95 sebocytes. 
The combination of dexamethasone and TNF-α synergistically increases TLR-2 
gene expression. Recently, it was reported that synthetic corticosteroid budesonide 
enhances TLR-2 gene expression in both un-stimulated and lipopolysaccharide-
treated keratinocytes82.  
This study tried to assess the intracellular signaling mechanism of glucocorticoid-
enhanced TLR-2 gene expression by using several inhibitors and an activator. All 
of the data suggested that TLR-2 gene expression was negatively regulated by p38 
mitogen-activated protein kinase (MAPK). These data suggest that p38 MAPK is 
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closely associated with dexamethasone-induced TLR-2 gene expression in SZ95 
sebocytes.  
Taken together, psychological stress induced α-MSH and glucocorticoids induce 
not only sebum secretion but also inflammation in acne vulgaris. The present 
findings suggest that receptors of α-MSH and HSD11β1 might be a future target 
for therapeutic intervention for the treatment of acne vulgaris. 
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V. CONCLUSION 
The aim of this study is to investigate the sebogenesis-inducing effects of α-
MSH, mediated by either MC1R or MC5R expression and differentiation status of 
sebocytes. This study also investigated the effects of HSD11β1 on sebogenesis in 
sebocytes. Lastly, this study investigated whether there is a possible cross-talk 
between α-MSH and HSD11β1 in acne vulgaris pathogenesis. The summary of the 
results are described below: 
 
1. The effect of α-MSH on the lipogenesis of sebocytes was greater in the T/LA-
induced differentiated sebocytes than in the undifferentiated cells. α-MSH 
induces lipid synthesis in SZ95 sebocytes by induction of SREBP-1c via the 
IP3/PLC pathway. 
 
2.  SREBP-1a and 1c involves lipid synthesis in SZ95 sebocytes by 
dexamethasone. Specific inhibitors of HSD11β inhibited HSD11β1 gene 
expression, lipid droplets, and SREBP-1 gene expression that were induced by 
dexamethasone. The IL-1α, IL-6 and TNF-α increased HSD11β1 gene 
expression. 
 
 
3. α-MSH enhanced TLR-2 gene expression in differentiated SZ95 sebocytes. 
Dexamethasone remarkably enhanced TLR-2 gene expression in SZ95 
sebocytes. The combination of dexamethasone and TNF-α synergistically 
increased TLR-2 gene expression. TLR-2 gene expression was negatively 
regulated by p38 mitogen-activated protein kinase (MAPK).  
 
In conclusion, psychological stress induced α-MSH and glucocorticoids induce not 
only sebum secretion but also inflammation in acne vulgaris.   
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ABSTRACT (IN KOREAN) 
 
α-멜라닌세포자극호르몬과 11β-하이드록시스테로이드 
탈수산화효소가 SZ95 피지세포의 피지생성에 미치는 영향 
 
<지도교수 이승헌> 
 
연세대학교 대학원 의과학과 
 
김지민 
 
여드름은 모낭 피지기관의 만성 염증성 재발성 피부질환으로 임상적으
로 면포, 농포, 결절, 낭종 등이 피지분비가 많은 얼굴, 목, 가슴 등에 나
타나며 주로 사춘기에 발생하는 질환이다. 여드름의 병인은 모낭벽의 과
각화, 피지분비의 증가, 여드름균의 증식 염증유발 등 크게 4가지로 언급
되고 있다. 그러나 최근에는 이들 4가지 외에 정신적 스트레스에 의하여 
여드름이 발생하는 기전을 추가적인 병인으로 제시하고 있다. 스트레스에 
의해 시상하부－뇌하수체－부신축이 활성화 되면서 멜라노코르틴 
(melanocortin)과 당질코르티코이드 (glucocorticoids)와 같은 다양한 호르몬
의 분비를 증가시킨다. 멜라노코르틴 중 하나인 α-멜라닌세포자극호르몬 
(α-MSH) 은 자신의 수용체인 MC1R 과 MC5R에 결합한다. α-MSH 은 인
간 피지세포의 피지생성을 증가시키는 것으로 잘 알려져 있으며, 또한 최
근 연구 결과에서 α-MSH이 피지세포의 MC1R을 통하여 세포 내 칼슘 이
온 반응과 같은 중요 세포 신호 경로를 담당하는 것이 보고 되었다. 당질
코르티코이드는 숙주의 중요한 생리조절활성기능을 조절한다. 비록 당질
코르티코이드가 면역억제 및 항염증성 효능을 가지고 있지만, 임상적으로 
전신 또는 국소 적인 당질코르티코이드 치료가 여드름 형성 반응을 불러
일으키는 것 또한 잘 알려져 있다. 11β-하이드록시스테로이드 탈수산화효
소 (HSD11β1)는 비활성 코르티손 (cortisone)을 활성화 된 코르티졸 
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(cortisol)로 전환하여 세포 내 당질코르티코이드 농도를 조절하는 역할을 
한다.  
인간의 피지세포가 α-MSH의 직접적인 세포 표적인 것은 자명해 보이나 
아직까지 인간의 피지 샘에서 발현된 멜라노코르틴 수용체의 생물학적 
영향에 대한 기전은 완전히 밝혀지지 않았다. 또한 당질코르티코이드가 
피지생성에 미치는 영향 및 HSD11β1의 관여 가능성에 대한 연구는 아직
까지 보고된 바 없다. 따라서 본 연구에서는 첫 번째로 피지세포의 분화 
상태에 따라서 다르게 나타나는 MC1R 혹은 MC5R을 통한 α-MSH이 피
지세포의 피지생성 및 염증성 사이토카인과 톨유사수용체-2 (toll-like 
receptor 2, TLR-2)의 발현에 미치는 영향에 대한 연구를 수행하였으며, 다
음으로 피지세포에서의 HSD11β1의 발현과 사이토카인에 의한 발현 조절
에 대한 연구 및 HSD11β1가 피지세포의 피지생성에 미치는 영향에 대한 
연구를 수행하였다.  
그 결과, MC5R의 발현은 오직 분화된 SZ95 피지세포에서만 확인 되었
으며 분화된 세포 내에서 α-MSH에 의해 세포 내 피지 양의 증가가 분화
되지 않은 세포에서 보다 더 높은 것을 확인하였다. 또한, SREBP-1a가 아
닌 오직 SREBP-1c mRNA 의 발현만이 α-MSH에 의해 증가 되었으며, 이
러한 증가는 IP3 수용체의 길항제 및 PLC 저해제에 의해 억제되는 것을 
미분화 세포 와 분화 세포에서 확인하였다. 다음으로 SZ95 피지세포 내
에서 HSD11β1의 발현이 dexamethasone에 의해 증가하는 것을 확인하였으
며 이는 당질코르티코이드 수용체의 길항제인 RU-486, 퍼옥시좀 증식체 
활성화 수용체-γ (PPAR-γ) 활성제인 pioglitazone 및 HSD11β1 특정 억제제
인 PF-915275에 의해 억제되었다. 이와 유사하게, dexamethasone에 의한 
SZ95 피지세포의 피지생성 증가 또한 RU-486, PF-915275 및 pioglitazone에 
의해 억제되었다. 뿐만 아니라 dexamethasone에 의한 SREBP-1a 과 1c의 
mRNA의 발현 증가 역시 RU-486, PF-915275 및 pioglitazone에 의해 억제
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되었다. 다음으로 α-MSH가 IL-1α, IL-6 그리고 TNF-α와 같은 염증성 사이
토카인의 유전자 발현을 미분화 및 분화된 세포에서 모두 증가시키는 것
을 확인하였다. 또한 이러한 IL-1α, IL-6 그리고 TNF-α를 SZ95 피지세포에 
처리하였을 때 HSD11β1의 유전자 발현이 증가하는 것을 확인하였다. 마
지막으로 α-MSH에 의한 TLR-2 유전자 발현의 증가는 오직 분화된 세포
에서만 나타났다. dexamethasone 또한 SZ95 피지세포 내 TLR-2 유전자 발
현을 증가 시키는 것을 확인하였으며 TNF-α와 함께 dexamethasone은 
TLR-2 유전자 발현증가에 시너지 효과를 나타내었다.  
이러한 모든 결과를 바탕으로 정신적인 스트레스에 의해 유도된 α-MSH 
와 당질코르티코이드는 여드름 에서의 피지 분비뿐만 아니라 염증반응에
도 관여하는 것으로 보인다. 나아가서, 이러한 연구 결과를 바탕으로 α-
MSH 수용체 와 HSD11β1는 여드름 치료를 위한 새로운 대상이 될 수 있
다고 생각된다. 
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